Harnessing the Natural Tropism of Mesenchymal Stem Cells to Cancer in A Drug Targeting Platform

NanoGhost is a biotech company that develops a highly selective first-in-class drug targeting platform (Nano-Ghosts/NGs) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation.

​

NGs are nanovesicles equipped with inherent MSC targeting capabilities, ability to infiltrate inter and intra cellular niches, with versatile loading capacity and broad therapeutic applicability.

 

This technology is based on discoveries from the lab of Prof. Marcelle Machluf, Technion Institute of Technology, Israel.